Porownywarka

Argireline vs GHK-Cu side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

ArgirelineGHK-Cu

Udostępnij porównanie peptydów

Wlasciwosc	Argireline	GHK-Cu
Kategoria	Skóra i włosy	Skóra i włosy
Znany tez jako	Acetyl Hexapeptide-3, Acetyl Hexapeptide-8	Copper Peptide, Glycyl-L-histidyl-L-lysine copper
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Cosmetic use - widely available Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Wrinkle reduction, forehead lines, eye area anti-aging	Skin rejuvenation, wound healing, hair growth, anti-aging
Jak dziala	Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.	GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.
Typowe dawkowanie	Limited community data available · See research protocols	1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application
Dawkowanie z badań	5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)	1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application
Typowy czas trwania	Ongoing use for maintained effects	Varies by application
Podanie	Topical (serums, creams)	Subcutaneous injection or topical application
Timing	Morning and evening (topical) With or without food	Evening for skin or recovery contexts With or without food
Poziom dowodów	Badawcze	Badania kliniczne
Mozliwe skutki uboczne	Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.) Mild skin irritation (Rare in the supplied source.) Redness or tingling (Rare in the supplied source.) +1 więcej Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)	Generally well tolerated (Reported as a general tolerability statement in the source.) Mild topical irritation, redness, or tingling (Associated with topical use.) Injection-site reactions (Associated with injectable use.) +4 więcej Possible histamine release (Source advises caution for MCAS or histamine sensitivity.) Copper toxicity risk with excessive use (Risk described for excessive exposure.) Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.) Caution with active cancer (Source flags an angiogenesis-related concern.)
Podsumowanie researchu	The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.	The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.
Referencje	PubMed Wiley Online Library +3 więcej PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Argireline

GHK-Cu

Kategoria

Skóra i włosy

Znany tez jako

Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

Copper Peptide, Glycyl-L-histidyl-L-lysine copper

Zatwierdzony przez FDA

Nie

Status kliniczny

Cosmetic use - widely available

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Used in cosmetic products with limited human topical-skincare evidence; the source also notes injectable compounding restrictions and a pending reclassification process.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Wrinkle reduction, forehead lines, eye area anti-aging

Skin rejuvenation, wound healing, hair growth, anti-aging

Jak dziala

Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.

GHK-Cu is described as the copper(II) complex of the GHK tripeptide. The source connects its activity to copper binding and possible cellular copper delivery, but also emphasizes effects that go beyond a simple carrier model. Reported laboratory observations include shifts in gene expression, increased fibroblast production of extracellular-matrix components, keratinocyte support, vascular-related activity, and antioxidant or anti-inflammatory signals. The precise mechanism is still not fully defined.

Typowe dawkowanie

Limited community data available · See research protocols

1-2 mg daily injection or 0.05% topical · Once daily · Subcutaneous injection or topical application

Dawkowanie z badań

5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)

1-2 mg for injectable protocols · Varies by application · Subcutaneous injection or topical application

Typowy czas trwania

Ongoing use for maintained effects

Varies by application

Podanie

Topical (serums, creams)

Subcutaneous injection or topical application

Timing

Morning and evening (topical)

With or without food

Evening for skin or recovery contexts

With or without food

Poziom dowodów

Badawcze

Badania kliniczne

Mozliwe skutki uboczne

Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.)
Mild skin irritation (Rare in the supplied source.)
Redness or tingling (Rare in the supplied source.)

+1 więcej

Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)

Generally well tolerated (Reported as a general tolerability statement in the source.)
Mild topical irritation, redness, or tingling (Associated with topical use.)
Injection-site reactions (Associated with injectable use.)

+4 więcej

Possible histamine release (Source advises caution for MCAS or histamine sensitivity.)
Copper toxicity risk with excessive use (Risk described for excessive exposure.)
Wilson's disease contraindication (Source lists Wilson's disease as contraindicated.)
Caution with active cancer (Source flags an angiogenesis-related concern.)

Podsumowanie researchu

The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.

The source describes a mixed evidence base. Cell and animal work is reported for wound repair, collagen deposition, fibroblast activity, elastin and growth-factor production, keratinocyte protection, and lung-injury models. Human data are described as small topical cosmetic studies, including facial-cream and eye-cream studies with 71 and 41 participants that reported changes in skin density, thickness, and wrinkle appearance. These data are encouraging for topical skin endpoints but do not establish injected or systemic benefits.

Referencje

PubMed Wiley Online Library

+3 więcej

PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8

PubMed PubMed

+1 więcej

PubMed

Pełny profil

Zobacz szczegóły